An interventional study of Gamification and education with mobile game application in Gamification, Type 2 Diabetes and Self-management, sponsored by Sakarya University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Sakarya University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.
Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 148th largest by enrollment of the 266 interventional ones that give a count, is one of 31 that started in 2024, is one of 150 with no phase, and was the 182nd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Hatice Zehra FERHATLAR · Sites in Turkey
Ages 18–65
Ankara Medipol University · Sites in Turkey
Ages 18–74
AstraZeneca · Sites in Turkey, United States, Argentina and 8 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 85 · Phase 4 28
First in 2002; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is close to the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 266 interventional studies, 118 across the 75 observational. Of the 261 that completed or were terminated, 80 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 342 have an industry lead sponsor. The 10 most frequent:
Sakarya University is the lead sponsor of 191 studies on the registry; 53 are open to participants now.
Sakarya University has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
25 of the studies in Diabetes Mellitus, Type 2 with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847294Ankara Medipol UniversityThe Effectiveness of an Occupation-Based Lifestyle Program in Individuals With Type 2 Diabetes | 2026-11 |
| NCT07659925Baskent UniversityPeriodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes | 2026-11 |
| NCT07734428Istanbul Bilgi UniversityInflammation and Diabetes: Evaluating Antioxidant Levels | 2026-12-30 |
| NCT07649967Selcuk UniversityValidity and Reliability of Mixed Reality-Based Functional Mobility Tests in Type 2 Diabetes | 2026-12-30 |
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2027-01-15 |
Add all 25 to your calendar (.ics) → With an account.
Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes is a broad-spectrum metabolic disorder that causes a defect in the organism's carbohydrate, fat, and protein metabolism processes due to insulin deficiency or impaired insulin effect. Diabetes requires continuous medical care and causes chronic, severe mortality and morbidity. More than 90% of all people with diabetes worldwide suffer from Type 2 DM. Diabetes self-management includes self-monitoring of blood glucose levels, knowing and managing the symptoms of hypoglycemia and hyperglycemia, adherence to diet, physical exercise, and diabetic foot care. Considering the high prevalent and undesirable consequences of diabetes in the world, it is necessary to benefit from new educational technologies and tools. One of these technologies is gamification, which increases the quality of education as an effective educational tool, creates motivation and enthusiasm, and develops a sense of competition in the target audience. This study plans to develop a game that will include virtual coaching to increase the self-management and glycemic control of patients with type 2 diabetes.
The research will be carried out in two stages. In Stage 1, the game will be developed; The developed game's effectiveness will be evaluated in the 2nd stage by testing it. The game's content will include healthy nutrition, exercise, foot care, insulin use, and hypoglycemia management. When the games are completed, the virtual coach will step in, and the participants will be given motivational feedback. The game developed will be evaluated by the patients in the second stage with a two-week pilot period. It will be updated according to the feedback received. The final version of the game will be passed forward to the implementation phase. Individuals who are willing to participate in the study coming to Prof. Dr. Cemil Tascioglu City Hospital Diabetes Polyclinic will be randomly assigned to the intervention and control groups. A total of 88 patients (44 controls - 44 experiments) are planned to be recruited. In the first interview with the individuals in the intervention group, Within the scope of the pretest, the "Personal Information Form," "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" will be used for evaluation. Outpatient appointment dates of the 12th week of the intervention program, "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" forms will be used with patients for the final evaluation within the scope of the posttest.
In the first meeting with the individuals in the control group, explanations about the research will be made. After their written consent is obtained at the first interview and within the scope of the pretest, the "Personal Information Form," "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" will be used for evaluation. At the end of the 12th week of the study, when they come in for their outpatient clinic appointments, as a part of the posttest, "Anthropometric Measurement Form," "Metabolic Control Variables Form," and "Diabetes Self-Management Scale" forms will be used for the final evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Application of data collection forms for the initial evaluation. Teaching the use of mobile games, monitoring the use of mobile games in the experimental group by the researcher for 12 weeks, and applying data collection forms to the patients in the 12th week.
Other: Gamification and education with mobile game application
Application of data collection forms for the initial evaluation. Application of data collection forms to the patients in the 12th week. No intervention will be made to the patients in the control group other than the routine education given in the diabetes outpatient clinic.
This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
self-management scale
Determining whether or not the disease self-management scale scores in patients with Type 2 DM using the developed mobile game application increased at the end of the 12 weeks period. A minimum of 0 and a maximum of 10 points are obtained on the scale. If an item is skipped, it is evaluated as -3 points. Diabetes self-management increases as the score get closer to 10.
Time frame: Change between the first day and the 12- week of the study
glycemic control (HbA1c)
The effect that the mobile game application developed imposes on glycemic control in patients with Type 2 DM at 12 weeks compared to baseline. The effect of the patient's HbA1c tests on the 12th week compared to the baseline. Blood test (HbA1c) will be performed during the outpatient follow-up at the first and 12th weeks.
Time frame: Change between day one and week 12 of the study
anthropometric measurements (Body Mass Index)
The effects on anthropometric measurements in patients with Type 2 DM using the mobile game application developed compared to baseline at week 12. The effect on the patient's Body Mass Index compared to baseline at week 12. The researcher will measure it. Body Mass Index is calculated by dividing the person's weight in kilograms by the square of the person's height in meters (kg/m²).
Time frame: The change between the first day and the 12th week of the study
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Mar 2025, 8 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 8 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Feb 2023 → Jun 2024, primary completion Sep 2023 → Mar 2025 and completion Dec 2023 → Mar 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.